All In Biotech

Drug Trial Radar · NCT05598268

A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.

A Phase I/IIa Study to Assess the Safety, Tolerability, Biodistribution and Pharmacodynamic of T3011 Herpes Virus Administered Via Intravenously in Patients With Advanced Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Oct 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

74

Planned (sponsor's estimate)

Start

Mar 1, 2022

Primary completion

Jun 2024

Study completion Dec 2024

Sponsor

Lead sponsor
ImmVira Pharma Co. LtdIndustry
Sponsor type
Industry
First posted
Oct 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label study conducted in 3 phases: Dose escalation stage: The stage contain 4 cohorts, each cohort divided into 2 groups (group A, single dose and Group B, multiple dose).Dose escalation will use a 3+3 design to evaluate escalating doses of T3011.Cohorts of three subjects will be enrolled at each T3011 dose level with expansion to six subjects, if necessary, to assess toxicity. Total enrollment will depend on the toxicities observed, with approximately 4-24 evaluable subjects enrolled in dose escalation stage. Dose extension stage: The SMC will evaluate the available safety and preliminary efficacy data and initiate dose-expansion studies for the appropriate indications Phase IIa: To explore the safety of intravenous administration and expand the study in other indications. the stage will be carried out gradually based on the data obtained from the phase I study.

Conditions

  • Advanced Solid Tumor
  • Lung Cancer
  • Liver Cancer
  • Lymphoma
  • Mesothelioma of Pleura

Interventions

  • T3011Biological

    T3011 will be administered through IV drip

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of escalating doses of IV T3011 in Patients with advanced malignant tumorsTime frame: Up to 2 years from first dose of T3011
  2. Assess DLTs and identify the RP2D of single agent IV T3011Time frame: Up to 2 years from first dose of T3011
  3. Assess safety and tolerability of T3011 intravenous administration at MTD or RP2D doses through dose extension studyTime frame: Up to 2 years from first dose of T3011

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chest Hospital

    Beijing, China · Recruiting

  • Shanghai Chest Hosptial

    Shanghai, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medicial College

    Bengbu, Anhui, China · Recruiting

  • Zhujiang Hospital of Southern Medical University

    Guanzhou, Guangdong, China · Recruiting

  • the First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Recruiting

  • Henan Cancer Hosptial

    Zhengzhou, Henan, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.